ScreenerHero

IKT Inhibikase Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · inhibikase.com
1.940USD-2.02%Mkt Cap: 270.70M $P/E: —

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH)…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap270.70M USD
Enterprise Value201.49M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-48.26M USD
Revenue/Share—
Last Price1.940 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees35
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.58
PEG—
EV/EBITDA-3.04
EV/Revenue—
P/S—
P/B2.26
EPS (TTM)-0.43
EPS (Forward)-0.43
52W Range
1.33048% of range2.610
52W High2.610 USD
52W Low1.330 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-27.91%
ROA-26.63%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.79M USD
CapEx (TTM)452.02K USD
FCF Margin—
FCF Yield-8.16%
Net Debt-159.02M USD
Net Debt/EBITDA2.40
Balance Sheet
Debt/Equity0.00
Current Ratio15.82
Quick Ratio15.50
Book Value/Sh0.88 USD
Cash/Share0.87 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJun 30, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.000 USD
Upside (mean)+209.3%
Target Range3.000 USD – 8.000 USD
3.000+209.3% to mean8.000
# Analysts9
Ownership
Shares Out.139.54M
Float107.13M
Insiders6.09%
Institutions89.73%
Short Interest
Short Ratio45.5d
Short % Float20.67%
Short % Out.13.27%
Shares Short18.52M
Short (prev mo.)19.67M
Technical
SMA 502.319 (-16.3%)
SMA 2001.943 (-0.2%)
Beta0.90
S&P 52W Chg16.45%
Avg Vol (30d)534.55K
Avg Vol (10d)488.87K
Technical Indicators
RSI (14)33.6
MACD-0.1022
MACD Signal-0.0781
MACD Hist.-0.0241
BB Upper2.508 USD
BB Middle2.165 USD
BB Lower1.823 USD
BB Width31.62%
ATR (14)0.1010 USD
Vol Ratio (20d)0.78x